奥氮平治疗精神分裂症的开放性临床研究  

A open-label study on the efficacy and safety of generic olanzapine in the management of schizophrenia

作　　者：司天梅[1] 于欣[1] 石川[1] 陈玉芳[1] 郭艳梅[2] 

机构地区：[1]北京大学第六医院,北京100083 [2]河北省精神卫生中心

出　　处：《精神医学杂志》2008年第1期3-5,共3页Journal of Psychiatry

摘　　要：目的评价国产奥氮平开放性治疗精神分裂症的疗效和安全性。方法开放、前瞻性研究设计。研究对象为符合DSM-IV精神分裂症诊断标准的门诊和住院患者。采用可变剂量国产奥氮平治疗8周,定期进行疗效和安全性评估,疗效指标为PANSS总分及分量表分和CGI,描述性记录不良事件和用锥体外系(EPS)不良反应量表评估EPS。结果共纳入83例患者,从治疗2周末起,PANSS总分及分量表分就有显着改善,治疗8周的PANSS总分减分率为57.3%,治疗有效率为66.3%。药物的平均起效时间为2.3周。治疗中主要发生的不良反应为嗜睡、体重增加和心悸,8周末1例患者空腹血糖升高。结论国产奥氮平治疗精神分裂症具有较好的疗效和安全性。Objective To explore the efficacy and safety of generic olanzapine in the management of schizo- phrenia. Methods A total of 83 subjects who met the DSM-IV criteria of schizophrenia were entered into a 8- week open-labeled trial of generic olanzapine. Subjects received baseline and 2 week, 4 week and end：of-study assessments. Efficacy parameters were PANSS and CGh The side effects were descriptive documented and assessed with ESRS. Results The patients experienced significant improvement in positive, negative and general psyphopathologic symptoms after 2 weeks of generic olanzapine treatment. This tendency continued to the end of trial. Reduction rate of PANSS total, comparing from the baseline, was 57.3%. The response rate was 66. 3 % after 8 weeks of treatment. The estimated mean time of action was 2.3 weeks. The most common adverse effects were somnolence, weight gain and palpitation, one blood glucose level increased. Conclusion Generic olanzapine is an effective and safe medication to treat schizophrenia.

关 键 词：奥氮平 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]